Finance

Lists
532488:BOM
Divi's Laboratories Ltd
9 220,00 ₹
+1,99%
(+180,05) 1D
16 հոկ, 15:56:15 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 532488...
Open
9 013,35 ₹
High
9 247,50 ₹
Low
8 985,00 ₹
Mkt. cap
2,45 տրլն
Avg. vol.
33,69 հզր
Volume
17,22 հզր
Dividend
0,33%
Quarterly dividend
7,50 ₹
Ex-dividend date
24 հլս, 2026 թ.
P/E ratio
83,67
52-wk high
10 000,00 ₹
52-wk low
5 648,00 ₹
EPS
110,20 ₹
Shares outstanding
265,47 մլն
No. of employees
12 հզր
Open
9 013,35 ₹
High
9 247,50 ₹
Low
8 985,00 ₹
Mkt. cap
2,45 տրլն
Avg. vol.
33,69 հզր
Volume
17,22 հզր
Dividend
0,33%
Quarterly dividend
7,50 ₹
Ex-dividend date
24 հլս, 2026 թ.
P/E ratio
83,67
52-wk high
10 000,00 ₹
52-wk low
5 648,00 ₹
EPS
110,20 ₹
Shares outstanding
265,47 մլն
No. of employees
12 հզր
News stories
From web sources and news partners
Profile
Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients and intermediates, headquartered in Hyderabad. The company manufactures and custom synthesizes generic APIs, intermediates. The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals. Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization. Wikipedia
About Divi's Laboratories Ltd
CEOKiran S. Divi
Employees11,6 հզր
Founded12 հոկ, 1990 թ.
Headquarters-
Sector-
Last report
01 օգս, 2026 թ.
Fiscal period
Q1 2027
33,95 ₹ / 24,68 ₹
+37,58%beat
Revenue / Est. (INR)
30,80 մլրդ / 27,61 մլրդ
+11,56%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
27,15 մլրդ
26,04 մլրդ
28,31 մլրդ
30,80 մլրդ
Cost of goods sold
10,73 մլրդ
9,45 մլրդ
13,49 մլրդ
9,86 մլրդ
Cost of revenue
10,73 մլրդ
9,45 մլրդ
13,49 մլրդ
9,86 մլրդ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,54 մլրդ
3,67 մլրդ
3,99 մլրդ
4,08 մլրդ
Operating expense
8,67 մլրդ
8,87 մլրդ
6,68 մլրդ
9,65 մլրդ
Total operating expenses
19,40 մլրդ
18,32 մլրդ
20,17 մլրդ
19,51 մլրդ
Operating income
7,75 մլրդ
7,72 մլրդ
8,14 մլրդ
11,29 մլրդ
Other non operating income
820,00 մլն
690,00 մլն
-2,23 մլրդ
640,00 մլն
EBT including unusual items
9,12 մլրդ
7,80 մլրդ
9,63 մլրդ
11,80 մլրդ
EBT excluding unusual items
9,12 մլրդ
8,54 մլրդ
9,59 մլրդ
11,80 մլրդ
Income tax expense
2,23 մլրդ
1,97 մլրդ
2,12 մլրդ
2,78 մլրդ
Effective tax rate
24,45%
25,26%
22,01%
23,56%
Other operating expenses
4,00 մլրդ
4,02 մլրդ
1,49 մլրդ
4,24 մլրդ
Net income
6,89 մլրդ
5,83 մլրդ
7,51 մլրդ
9,02 մլրդ
Net profit margin
25,38%
22,39%
26,53%
29,29%
Earnings per share
25,97
24,07
28,31
33,95
Interest and investment income
-
-
2,84 մլրդ
-
Interest expense
-80,00 մլն
-60,00 մլն
-60,00 մլն
-60,00 մլն
Net interest expenses
-80,00 մլն
-60,00 մլն
2,78 մլրդ
-60,00 մլն
Depreciation and amortization charges
1,13 մլրդ
1,18 մլրդ
1,20 մլրդ
1,33 մլրդ
EBITDA
8,88 մլրդ
8,72 մլրդ
9,29 մլրդ
12,44 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps